Human immunoglobulin (IG) is used for IgG replacement therapy in primary and secondary
immunodeficiency, for prevention and treatment of certain infections, and as an …

Blood safety remains an important public health concern in Africa where lack of availability
or provision of unsafe blood adversely impacts morbidity and mortality in the region. In …

Rapid chilling causes glycoprotein-Ib (GPIb) receptors to cluster on blood platelets. Hepatic
macrophage β2 integrin binding to β-N-acetylglucosamine (β-GlcNAc) residues in the …

BACKGROUND: Transfusion of platelet concentrates (PCs) is the basic treatment for severe
platelet disorders. PCs carry the risk of pathogen transmission, especially bacteria …

Transfusion-transmitted infections (TTI) have been greatly reduced in numbers due to the
strict donor selection and screening procedures, ie the availability of technologies to test …

Since 1990, several techniques have been developed to photochemically inactivate
pathogens in platelet concentrates, potentially leading to safer transfusion therapy. The …

Besides the current efforts devoted to microbial risk reduction, pathogen inactivation
technologies promise reduction of the residual risk of known and emerging infectious …

Platelet concentrates account for near 10% of all labile blood components but are
responsible for more than 25% of the reported adverse events. Besides factors related to …

The aim of the work is a literature review of published clinical studies on the effects of
hyperuricemia on the course of chronic heart failure (CHF). Results. High levels of uric acid …

The use of pathogen reduction technologies (PRT s) for labile blood components is slowly
but steadily increasing. While pathogen‐reduced plasma is already used routinely, efficacy …